Negotiations on the return of benefits of the 'Choline alfoscerate' legislation, which was the subject of the revaluation project of the listed drugs, have been concluded. However, the controversy over the return rate has not ended.

The NHIS negotiated with 58 pharmaceutical companies that owned 123 Choline alfoscerate on August 10. It announced that it has agreed with 44 pharmaceutical companies on a 20% return rate. Chong Kun Dang, which had been conducting PVA in the third quarter of this year, also finished negotiations. There are about 10 pharmaceutical companies that have not agreed.

Negotiations on the repatriation of Choline alfoscerate lasted about eight months from December 14 t